title: My approach to the diagnosis of mesothelial lesions.
abstract: Mesothelial lesions pose considerable diagnostic challenges not only because benign tumours, reactive proliferations and malignant mesothelioma can mimic one another, but also because the morphological patterns displayed by malignant mesothelioma can simulate a variety of epithelial and non-epithelial malignancies. Immunohistochemical markers can aid in distinguishing epithelioid malignant mesothelioma from metastatic adenocarcinoma, but because no single marker reliably separates all cases, a panel of stains is recommended. Immunohistochemical studies are of more limited value in sarcomatoid malignant mesothelioma, and other features often play an essential role. The separation of reactive mesothelial proliferations from malignant mesothelioma on small biopsy can be quite difficult, as distinguishing features, such as stromal invasion, often cannot be adequately assessed. In adequately sampled lesions, however, the distinction between malignant mesothelioma, benign mesothelial proliferations and other tumours can be achieved in most cases by using a carefully integrated approach that incorporates clinical and radiographic data, immunohistochemical studies and, in selected cases, histochemical and ultrastructural techniques.
authors.affiliation: University of Vermont/Fletcher Allen Health Care, Burlington, VT 05401, USA. kelly.butnor@vtmed-net.org
authors.forename: K J
authors.initials: KJ
authors.lastname: Butnor
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000473:pathology / Q000556:secondary; D014408:Biomarkers, Tumor / Q000378:metabolism; D049109:Cell Proliferation; D003937:Diagnosis, Differential; D004848:Epithelium / Q000473:pathology; D006801:Humans; D008654:Mesothelioma / Q000378:metabolism / Q000473:pathology*; D010997:Pleural Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000556:secondary
chemical_list: D014408:Biomarkers, Tumor